

Resource Summary Report

Generated by SPARC SAWG on Aug 9, 2026

Augusta University Georgia Cancer Center Flow and Mass Cytometry Core Facility

RRID:SCR_025747

Type: Tool

Proper Citation

Augusta University Georgia Cancer Center Flow and Mass Cytometry Core Facility
(RRID:SCR_025747)

Resource Information

URL: <https://www.augusta.edu/cancer/research/shared-resources/flow-and-mass/index.php>

Proper Citation: Augusta University Georgia Cancer Center Flow and Mass Cytometry Core Facility (RRID:SCR_025747)

Description: Core provides access to flow and mass cytometers, support equipment, and associated software and services. Our instrumentation affords the ability to perform almost every published flow and mass cytometry protocol.

Synonyms: Georgia Cancer Center Flow and Mass Cytometry Core

Resource Type: core facility, access service resource, service resource

Keywords: flow cytometry, mass cytometers,

Resource Name: Augusta University Georgia Cancer Center Flow and Mass Cytometry Core Facility

Resource ID: SCR_025747

Alternate IDs: ABRF_2927

Alternate URLs: <https://coremarketplace.org/?FacilityID=2927&citation=1>

Record Creation Time: 20240918T053245+0000

Record Last Update: 20260808T190730+0000

Ratings and Alerts

No rating or validation information has been found for Augusta University Georgia Cancer Center Flow and Mass Cytometry Core Facility.

No alerts have been found for Augusta University Georgia Cancer Center Flow and Mass Cytometry Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Komaravolu RK, et al. (2026) Age-associated chemokine receptor expression profiles in human peripheral blood monocyte subsets predict cardiovascular disease risk. *Frontiers in immunology*, 17, 1749366.

Murphy SA, et al. (2026) CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation. *Journal for immunotherapy of cancer*, 14(1).

Parvin M, et al. (2026) Therapeutically Engineering Exosomes to Target CD206+ M2 Macrophages to Prevent the Development of Primary Tumors and Distal Metastases in Breast Cancers. *Cancers*, 18(10).

Lu X, et al. (2026) BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBP β . *MedComm*, 7(5), e70747.

Chatterjee N, et al. (2026) Unveiling patterns: an exploration of machine learning techniques for unsupervised feature selection in single-cell data. *Briefings in bioinformatics*, 27(1).

Shi H, et al. (2026) Chemotherapy-induced reactive myelopoiesis promotes expansion of immunosuppressive neutrophil-like monocytes in mice and humans. *JCI insight*, 11(10).

Liu L, et al. (2026) Immunometabolic remodeling of perivascular adipose tissue in murine lupus: implications for lupus vasculopathy. *bioRxiv : the preprint server for biology*.

Walton SD, et al. (2026) Protective effects of fermentable dietary fiber and propionate in Dahl salt-sensitive hypertension and renal damage. *American journal of physiology. Renal physiology*, 330(2), F170.

Okoko OD, et al. (2026) Indomethacin exerts both cyclooxygenase inhibition-dependent and independent mechanisms to enhance chemo-immunotherapy in mice. *bioRxiv : the preprint server for biology*.

Rivera-Caraballo KA, et al. (2026) Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis. *Cancer research*, 86(5), 1232.

Gazi MY, et al. (2026) Targeting phosphodiesterase 10A disrupts MAPK signaling pathways in the tumor microenvironment to unleash antitumor immunity. *bioRxiv : the preprint server for biology*.

Zhang T, et al. (2025) Genomic Analysis Defines Increased Circulating, Leukemia-Induced Macrophages That Promote Immune Suppression in Mouse Models of FGFR1-Driven Leukemogenesis. *Cells*, 14(19).

Parashar S, et al. (2025) ER stress induced mitochondrial dysfunction drives Treg instability in coronary artery disease. *EMBO molecular medicine*, 17(12), 3250.

Bokhtia RM, et al. (2025) Biotin-Linked Ursolic Acid Conjugates as Selective Anticancer Agents and Target-Identification Tools for Cancer Therapy. *Molecules (Basel, Switzerland)*, 30(23).

Roy P, et al. (2025) Loss of effector Treg signature in APOB-reactive CD4⁺ T cells in patients with coronary artery disease. *Nature cardiovascular research*, 4(7), 841.